<?xml version="1.0" encoding="UTF-8"?>
<?xml-stylesheet type="text/xsl" href="https://www.nitrc.org/themes/nitrc3.0/css/rss.xsl.php?feed=https://www.nitrc.org/export/rss20_forum.php?forum_id=2992" ?>
<?xml-stylesheet type="text/css" href="https://www.nitrc.org/themes/nitrc3.0/css/rss.css" ?>
<rss version="2.0"> <channel>
  <title>NITRC News Group Forum: acute-baclofen-diminishes-resting-baseline-blood-flow-to-limbic-structures--a-perfusion-fmri-study.</title>
  <link>http://www.nitrc.org/forum/forum.php?forum_id=2992</link>
  <description>
	&lt;table border=&quot;0&quot; width=&quot;100%&quot;&gt;&lt;tr&gt;&lt;td align=&quot;left&quot;/&gt;&lt;/tr&gt;&lt;/table&gt;
        &lt;p&gt;&lt;b&gt;Acute baclofen diminishes resting baseline blood flow to limbic structures: A perfusion fMRI study.&lt;/b&gt;&lt;/p&gt;
        &lt;p&gt;Drug Alcohol Depend. 2012 Apr 16;&lt;/p&gt;
        &lt;p&gt;Authors:  Franklin TR, Shin J, Jagannathan K, Suh JJ, Detre JA, O'Brien CP, Childress AR&lt;/p&gt;
        &lt;p&gt;Abstract&lt;br/&gt;
        BACKGROUND: Preclinical and clinical evidence show that the GABA B agonist, baclofen is a promising treatment for addictive disorders; however, until recently its mechanism of action in the human brain was unknown. In previous work we utilized a laboratory model that included a medication versus placebo regimen to examine baclofen's actions on brain circuitry. Perfusion fMRI [measure of cerebral blood flow (CBF)] data acquired 'at rest' before and on the last day of the 21-day medication regimen showed that baclofen diminished CBF bilaterally in the VS, insula and medial orbitofrontal cortex (mOFC). In the present study, we hypothesized that a single dose of baclofen would have effects similar to repeated dosing. METHODS: To test our hypothesis, in a crossover design, CBF data were acquired using pseudo continuous arterial spin labeled (pCASL) perfusion fMRI. Subjects were either un-medicated or were administered a 20mg dose of baclofen approximately 110min prior to scanning. RESULTS: Acute baclofen diminished mOFC, amygdala, and ventral anterior insula CBF without causing sedation (family-wise error corrected at p=0.001). CONCLUSIONS: Results demonstrate that similar to repeated dosing, an acute dose of baclofen blunts the 'limbic' substrate that is hyper-responsive to drugs and drug cues. Smokers often manage their craving and can remain abstinent for extended periods after quitting, however the risk of eventual relapse approaches 90%. Given that chronic medication may not be a practical solution to the long-term risk of relapse, acute baclofen may be useful on an 'as-needed' basis to block craving during 'at risk' situations.&lt;br/&gt;
        &lt;/p&gt;&lt;p&gt;PMID: 22513380 [PubMed - as supplied by publisher]&lt;/p&gt;
    </description>
  <language>en-us</language>
  <copyright>Copyright 2000-2026 NITRC OSI</copyright>
  <webMaster></webMaster>
  <lastBuildDate>Mon, 27 Apr 2026 5:35:32 GMT</lastBuildDate>
  <docs>http://blogs.law.harvard.edu/tech/rss</docs>
  <generator>NITRC RSS generator</generator>
 </channel>
</rss>
